Year All20252024202320222021202020192018201720162015201420122011 Nov 7, 2017 Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress Oct 16, 2017 Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling Oct 11, 2017 Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 Aug 9, 2017 Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results Aug 2, 2017 Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference May 12, 2017 Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C May 5, 2017 Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress Apr 18, 2017 Ardelyx To Present at Upcoming Spring Medical Meetings Feb 27, 2017 Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference Feb 17, 2017 Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results